Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Vedana Therapeutics raises $46 million in Series A funding led by Westlake BioPartners and Canaan Partners to develop innovative migraine therapies.

PRIVATEJun 17, 2026•about 2 months ago

Amount Raised

$46 Million

Round Type

Series A

SeattleBiotechnologyHealth CareTherapeutics

Investors

Alexandria Venture InvestmentsDawn BiopharmaCanaan PartnersWestlake Bio Partners

Description

Vedana Therapeutics has secured $46 million in Series A financing to advance its next-generation therapies for migraine prevention. The financing was co-led by Westlake BioPartners and Canaan Partners, with support from Dawn Biopharma and Alexandria Venture Investments. The funds will help Vedana develop potentially best-in-class antibodies targeting clinically validated pathways for migraine control. The company's leadership includes experts who have significantly contributed to migraine therapy advancements.

Company Information

Company

Vedana Therapeutics

Location

Seattle, Washington, United States

About

Vedana Therapeutics is a biotechnology company focused on developing next-generation therapies for migraine prevention. Founded by leading migraine experts, the company aims to advance treatment options by targeting clinically validated pathways beyond current therapies. This includes developing potentially best-in-class, subcutaneously delivered antibodies. Their innovations intend to provide patients greater freedom from migraines by addressing limitations of existing treatments.

Predictive Intelligence
Strategic

ML-powered predictions for Vedana Therapeutics's next move

Learn about Strategic plan

Funding Insights

Based on industry data
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.